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Abstract
Objective: Persistent difficulty in using the upper limb remains a major contributor to physical 
disability post-stroke. There is a nihilistic view about what clinically relevant changes are possible 
after the early post-stroke phase. The Queen Square Upper Limb Neurorehabilitation programme 
delivers high quality, high dose, high intensity upper limb neurorehabilitation during a 3-week (90 
hour) programme. Here, we report clinical changes made by the chronic stroke patients treated 
on the programme,  factors that might predict responsiveness to therapy, and the relationship 
between changes in impairment and activity.
Methods: Upper limb impairment and activity were assessed on admission, discharge, 6 weeks 
and 6 months after treatment, with modified upper limb Fugl-Meyer, (FM-UL, max-54), Action 
Research Arm Test (ARAT, max-57) and Chedoke Arm and Hand Activity Inventory (CAHAI, max-
91). Patient reported outcome measures were recorded with the Arm Activity Measure (ArmA) 
parts A (0-32) and B (0-52), where lower scores are better.
Results: 224 patients (median time post-stroke 18 months) completed the 6 month programme. 
Median scores on admission were: FM-UL=26 (IQR 16-37), ARAT=18 (IQR 7-33), CAHAI=40 (28-55), 
ArmA-A=8 (IQR 4.5-12), ArmA-B=38 (IQR 24-46). The median scores 6 months after the 
programme were: FM-UL=37 (IQR 24-48), ARAT=27 (IQR 12-45), CAHAI=52 (IQR 35-77), ArmA-A=3 
(IQR 1-6.5), ArmA-B=19 (IQR 8.5-32). We found no predictors of treatment response beyond 
admission scores.
Conclusion: With intensive upper limb rehabilitation, chronic stroke patients can change by 
clinically important differences in measures of impairment and activity. Crucially, clinical gains 
continued during the 6 month follow up period.
Keywords: Stroke, rehabilitation, upper limb
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INTRODUCTION
Stroke remains common1 and persistent difficulty in using the upper limb is a major contributor to 
ongoing physical disability2. The general consensus remains that most spontaneous recovery of the upper 
limb occurs over the first three months after stroke and current levels of rehabilitation result in little 
improvement after that, particularly at the level of impairment3. Improving outcomes through higher dose 
(time in rehabilitation or number of repetitions) and intensity (dose per session) of rehabilitation is an 
attractive option4. However, clinical trials of higher dose upper limb rehabilitation have generally not 
produced the magnitude of improvement that will change clinical practice5, whether delivered in the early6 
or chronic stages post-stroke7–9.  A common factor in these trials is that the dose (in hours) of additional 
therapy remained relatively low (18-36 hours). Despite scepticism that stroke patients could tolerate much 
higher doses8, one study managed to deliverer 300 hours of upper limb therapy to chronic stroke patients 
over 12 weeks and reported changes in measures of both impairment and activity that were far greater 
than those in lower dose studies10. Three hundred hours represents an order of magnitude higher than any 
dose of rehabilitation offered in previous upper limb rehabilitation trials and deserves further 
consideration. However, this idea is challenging because of the logistics of setting up such a trial in health 
care settings where the ethic of high dose, high intensity rehabilitation is not supported. In this context, it 
is important to report the findings of clinical services that are able to deliver higher doses than 
conventionally seen. The Queen Square Upper Limb (QSUL) Neurorehabilitation programme is a single 
centre clinical service that provides 90 hours of timetabled treatment focusing on the post-stroke upper 
limb in chronic (> 6 months post-stroke) stroke patients. Here we report (i) outcomes for patients admitted 
to this programme at the National Hospital for Neurology and Neurosurgery, University College London 
Hospitals NHS Trust (UCLH), including 6 month follow up data to look at whether any clinical benefits were 
maintained, (ii) the characteristics of the patients admitted and any predictors of response and (iii) the 
relationship between changes in impairment and activity.
METHODS
Participants
Patients were referred by primary care physicians for advice about ongoing management of the paretic 
upper limb following stroke. There were no criteria around time since stroke. Clinical criteria warranting 
admission to the programme were broad but were focused on whether we felt able to help patients achieve 
their goals for the affected upper limb. Barriers to admission included factors precluding the ability to work 
in l upper limb tasks; (i) absent movements, throughout the limb; (ii) a painful shoulder limiting an active 
forward reach (mostly due to adhesive capsulitis); (iii) severe spasticity or non-neural loss of range; (iv) 
unstable medical conditions. These patients were not offered admission to the treatment programme, but 
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were provided with appropriate advice or referred for other treatment approaches. Re-referral to the 
programme was then considered (for example after successful management of adhesive capsulitis of the 
shoulder). Features that were more likely to result in admission to the programme included at least some 
ability to flex the shoulder and at least visible flickers of movement in finger and/or wrist extensors, 
although this was not always the case as reflected in baseline upper limb scores. Patients were admitted 
to the programme as day attenders, either from home or from the UCLH dedicated patient accommodation 
and as such were either self-caring, or self-caring with the support of one other person.
Interventions
Initial assessment consisted of analysis of both movement and performance in activities of daily living. 
Subsequent treatment was aimed at reducing impairment and promoting re-education of motor control 
within activities of daily living. Individualised meaningful tasks were practiced repeatedly in order to 
facilitate task mastery with a focus on quality of movement. This was achieved through (i) adaptation of 
the task, e.g. decomposing tasks into individual components to be practiced; (ii) adaptation of the 
environment, e.g. fabrication of functional splints and adaptation of tools such as cutlery or screwdrivers, 
to enable integration of the affected hand in meaningful activities; (iii) assistance, e.g. de-weighting the 
arm to allow strengthening and training of movement quality and control through increased range; (iv) 
independent task practice. Coaching was considered a key component of the programme, used throughout 
to embed new skills and knowledge into individual daily routines. Consequently, individuals increase 
participation and confidence in their desired goals, enhancing self-efficacy and motivation to sustain 
behavioural change beyond the end of the active treatment period. 
This overall approach was achieved through two daily sessions each of physiotherapy and occupational 
therapy, supplemented with tailored, individualized interventions, including repetitive practice with a 
rehabilitation assistant or robotic device, sensory retraining, use of dynamic and functional orthoses, 
neuromuscular electrical stimulation, and group work. Furthermore, patients were encouraged to work on 
cardiovascular fitness during the programme. A 6 hour timetable was implemented 5 days a week for 3 
weeks (total therapy time, 90 hours). Motor tasks could be described as passive or active, assisted or 
unassisted, functional or non-functional. Over the three weeks, the aim was to increase the time spent on 
active, unsupported functional tasks, depending on a patient’s level of impairment and progress. The 
programme was staffed with a 1:1 staff to patient ratio (2 physiotherapists, 2 occupational therapists, 2 
rehabilitation assistants for 6 patients).
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Quantitative assessment
All patients had the following baseline scores measured on admission (table 1): modified Rankin scale 
(mRS), Barthel Index (BI), Neurological Fatigue Index (NFI), Hospital Anxiety and Depression Scale (HADS), 
and sensation (as indexed by light touch on palm as described in Fugl-Meyer assessment of the upper 
extremity).
The affected upper limb was assessed on admission (T1), discharge (T2), 6 weeks (T3) and 6 months (T4) 
post-discharge, using the following measures: Fugl-Meyer (upper limb) (FM-UL), Action Research Arm Test 
(ARAT), Chedoke Arm and Hand Activity Inventory (CAHAI-13), Arm Activity Measure
The FM-UL is a stroke-specific, performance-based impairment index (where impairment refers to loss of 
body structure and function) with good validity and intra- and inter-rater reliability11,12. Here we have used 
a modified version of the FM-UL, excluding measures of co-ordination and reflexes based on hierarchical 
properties of the scale13, and as these do not relate to the upper limb synergies of interest14. The minimum 
clinically important difference (MCID) has been reported as 5.25 points 15.
The ARAT assesses a patient’s ability to handle objects differing in size, weight and shape and therefore can 
be considered to be an arm-specific measure of activity limitation16. The MCID has been suggested as 5.7 
points17.
The CAHAI-13 is a validated, upper-limb measure that uses a 13-point quantitative scale in order to assess 
recovery of the arm and hand in performing activities of daily living after a stroke18. It is a performance test 
using day to day items. It is not designed to measure the patient’s ability to complete the task using only 
their unaffected hand, but rather to encourage bilateral upper limb use. No MCID has been reported for 
CAHAI-13 (although the minimum detectable change is reported as 6.218).
The Arm Activity Measure (ArmA) is a patient reported outcome score19 with two components. The ArmA-A 
asks patients about their ability to care for their affected arm either themselves with their unaffected arm 
or  by  a  carer  or  a  combination  of  both  of these. ArmA-B asks patients about how easy or hard it is to 
use the affected arm in activities of daily living. For ArmA-A and ArmA-B, note that lower scores are better. 
No MCID has been reported for ArmA-A or ArmA-B.
Analysis plan
Our primary aim was to measure changes in upper limb deficit over time were examined using the Friedman 
test for all outcome scores. Post-hoc analysis to test differences between individual time points was carried 
out with the Wilcoxon signed-ranks test. As a secondary aim, we were then interested in whether baseline 
characteristics correlated with final (T4) outcomes. We initially examined for correlations between 
individual baseline characteristics and outcomes using Spearman’s rank correlation. We also tested 
whether median T4 outcomes were different depending on gender or side of lesion using Wilcoxon rank 
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sum test. Time since stroke was not considered as a covariate as once in the chronic phase, there is no 
indication that time since stroke has a linear effect on outcome. Lastly we performed multiple linear 
regression to look for predictors of either absolute scores at T4 or the change in scores T1 to T4.  Lastly, 
we also examined the relationship between the changes in outcome scores from admission to 6 month 
follow up using Spearman's rank correlation.
RESULTS
Baseline characteristics
Between January 2015 and December 2017, 268 patients were admitted to the QSUL programme 
(representing 46% of patients assessed in out-patient clinic). 40.4% of patients were admitted from home, 
whilst 59.6% stayed in the UCLH dedicated patient accommodation. Note, only 16 patients were admitted 
to the programme prior to 6 months post-stroke, and only 1 prior to 3 months, reflecting overall referral 
patterns to the programme. 
Of those, 30 were non-stroke (12 traumatic brain injury, 8 brain tumour, 3 peripheral neurological 
conditions, 3 spinal cord injury, 4 inflammatory central nervous system conditions) and are excluded from 
this analysis. A total of 238 stroke patients were admitted, of whom 224 completed follow up assessments 
at 6 weeks and 6 months after discharge from the programme. Of the 14 incomplete follow ups, 5 patients 
considered it too far to travel for follow up, 4 patients suffered intercurrent illness (recurrent stroke, 
fractured hip, complications of surgery, seizures), and 5 could not be contacted. Differences in median 
values between complete and missing data groups was tested with Wilcoxon Signed Rank test. Where 
appropriate, differences in proportions between complete and missing data groups were tested with Chi-
squared test. There were no differences in baseline characteristics between patients who completed follow 
up and those who were lost to follow up (table 1). Because (i) there was no systematic difference between 
subjects with complete data and those with missing data, and (ii) only outcome data (not explanatory 
variables, which were collected at T1) were missing, then missing data were dealt with by performing a 
complete case analysis (i.e. only using subjects where complete data were available).
Changes in upper limb deficit
The median scores for the affected upper limb at admission (T1), discharge (T2), 6 weeks (T3) and 6 months 
post-discharge (T4) are shown in table 2. The Friedman test was used to demonstrate a significant effect of 
time since admission for all outcome scores; FM-UL (χ2 (3) = 431.8, p<0.0001); ARAT (χ2 (3) = 383.2, 
p<0.0001); CAHAI (χ2 (3) = 371.6, p<0.0001); ArmA-A (χ2 (3) = 238.4, p<0.0001); ArmA-B (χ2 (3) = 305.6, 
p<0.0001). Post hoc analysis with Wilcoxon signed-ranks test was conducted to test the hypothesis that the 
difference between the paired values (T1-T2, T1-T3, T1-T4, T2-T3, T2-T4, T3-T4) comes from a distribution 
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whose median is zero (i.e. testing whether the change in score is significantly greater than zero). A 
Bonferroni correction was applied to the significance level for the 6 comparisons made for each of the 5 
different outcome scores (p<0.05/30 = 0.0017). For each outcome score, there was a significant difference 
between each pair of time points compared, except T2-T3 for the ArmA-A (table S1). Individual scores at 
each time point are shown in figures 1 and 2. Individual changes in scores in comparison to admission are 
shown in table 3 and figures 1 and 2. These results demonstrate improvement during the 3 week 
programme, but also continued improvement after discharge. 
By 6 months after the programme, 68.3% of patients had achieved greater than the MCID of 5.25 points on 
the FM-UL. For ARAT, this figure was 61.6%. No published MCID is published for the other scores. MCID is 
often quoted as 10% of the maximum score. If this were the case, then by 6 months, MCID would have 
been reached by 59.4% of patients for CAHAI, 53.8% for ArmA-A and 72.3% for ArmA-B.
Predictors of outcome
Firstly, we were interested to see whether any baseline characteristics (T1) correlated with final outcome 
at T4. Spearman’s rank correlation was used to show that admission values at T1 for FM-UL, ARAT, CAHAI, 
ArmA-A, ArmA-B all correlated with T4 values for FM-UL, ARAT, CAHAI, ArmA-A, ArmA-B. In addition, 
admission BI correlated with T4 CAHAI; admission mRS correlated with T4 FM-UL, ARAT and CAHAI; 
admission sensation correlated with T4 CAHAI. Age, NFI and HADS at T1 did not correlate with any scores 
at T4. All p-values were corrected for multiple comparisons by Bonferroni correction (Table 4). Figure 3 
helps to visualise the influence of baseline admission scores on final score at 6 month follow up. 
Furthermore, a Wilcoxon ranked sum test showed that T4 outcomes did not differ by gender or affected 
hemisphere. There was a trend for patients with non-dominant affected limbs to achieve better (lower) 
ArmA-B scores in comparison to those with dominant affected limbs (median 17 for non-dominant vs -27 
for dominant, p = 0.027, uncorrected). There were no differences in T4 scores between patients with 
dominant or non-dominant affected limbs for any of the other outcome scores.
Secondly, we were interested to see whether any baseline characteristics (T1) correlated with magnitude 
of change from admission to 6 months follow up (T1 to T4). Spearman’s rank correlation was used to show 
that FM-UL, ARAT, CAHAI and ArmA-B at T1 correlated with change in ARAT and CAHAI (but not FM-UL) 
from T1 to T4. FM-UL at T1 also correlated with change in ArmA-B from T1 to T4. ArmA-A at T1 correlated 
with change in both CAHAI and ArmA-A from T1 to T4. ArmA-B at T1 correlated with change in both ArmA-A 
and ArmA-B from T1 to T4. Age, NFI, HADS, BI and mRS at T1 did not correlate with any scores at T4. All p-
values were corrected for multiple comparisons by Bonferroni correction (table 5). We also performed a 
Wilcoxon ranked sum test to show that change in scores from T1 to T4 were not different depending on 
gender or affected hemisphere. There was a trend for patients with non-dominant affected limbs to 
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improve on the ArmA-B between T1 and T4 to a greater degree than those with dominant affected limbs 
(median changes of -17.5 for non-dominant vs -12 for dominant, p = 0.017, uncorrected). There were no 
differences in change scores between patients with dominant or non-dominant affected limbs for any of 
the other outcome scores.
We then performed multiple linear regression to look for predictors of either absolute scores at 6 months 
after treatment (T4) or the change in scores from admission to 6 months after treatment (T1 to T4) using 
age, BI, mRS, NFI, HADS and sensation on admission together with the matching initial score on admission 
(e.g. FM1 if attempting to predict FM4 or change from FM1 to FM4). Models predicting T4 scores for FM-
UL, ARAT, CAHAI, ArmA-A and ArmA-B were all highly significant (p<0.0001). Models predicting change 
from T1 to T4 for ARAT, CAHAI, ArmA-A and ArmA-B (but not FM-UL) were also highly significant (p<0.0001). 
However, the only factor that significantly contributed to these models was the matched initial score on 
admission (e.g. ARAT at T1 predicting ARAT at T4), but not age, BI, mRS, NFI, HADS or sensation on 
admission. As such, this approach did not contribute further to the correlation results shown in table 4 and 
5, with regression models not able to account for a higher proportion of variance in scores at T4 or change 
in scores from T1 to T4 than the admission score (see also Figure 3).
Relationship between outcome measures
Each outcome score assesses a different aspect of recovery. Using Spearman's rank correlation, we 
examined the relationship between the changes in outcome scores from admission to 6 month follow up. 
A Bonferroni correction was applied to the significance level for the 10 comparisons made between the 5 
different outcome scores (p<0.05/10 = 0.005) (Table 6 and Figure 4). Changes in FM-UL, ARAT and CAHAI 
correlated weakly with one another. The ArmA-B change correlated with changes in both ArmA-A and 
ARAT.
DISCUSSION
We report the results from a single centre clinical service delivering high dose and intensity of upper limb 
focused neurorehabilitation for people with stroke. Almost all of these patients were in the chronic (>6 
months after stroke) phase. The key messages from our results are (i) patients were able to complete the 
90 hours of the programme, despite exhibiting a range of impairments and fatigue levels,  (ii) large clinical 
improvements in upper limb impairment (FM-UL) and activity (ARAT, CAHAI, ArmA) were observed, and 
(iii) these changes were maintained, or even improved upon, 6 months after treatment. 
The QSUL programme is based on the hypothesis that a high dose and intensity of upper limb 
neurorehabilitation can lead to large clinically meaningful improvements in chronic stroke patients. It is 
worth comparing the magnitude of the changes with previous reported clinical trials of upper limb 
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rehabilitation. Most obviously, the study by McCabe et al10 investigated the effects of 300 hours of upper 
limb rehabilitation in 48 chronic stroke patients with similar characteristics to those reported here (baseline 
FM-UL 24, compared to 26 in our patients) and reported an increase of 8-11 points on the FM-UL at the 
end of 300 hours of upper limb treatment (although later follow up results have not been reported). In the 
QSUL programme, the median FM-UL (modified) improvement was 6 points after the 90-hour programme, 
increasing to 9 points by 6 months follow up, achieving a similar overall magnitude of change in comparison 
to McCabe et al. In addition to reductions in impairment (FM-UL), our patients also improved at the level 
of activity (ARAT and CAHAI) and participation (using the patient reported outcome measure, ArMA). 
Importantly, we report that these group level effects continued to improve at 6 weeks and then 6 months 
after treatment had stopped, (figure 1 and 2).
Other than the study by McCabe et al, the general view has been that large changes, especially in 
impairment, have not been seen for behavioural interventions of the post-stroke upper limb3. Direct 
comparison with other studies is difficult because some may have been conducted in less severely affected 
patients, the dose (measured in time) of the intervention may have been lower, and the numbers of 
patients enrolled has been much lower than we report here. Whilst this report of our single-centre clinical 
outcomes is not a replication of the McCabe study, it suggests that the next wave of upper limb 
rehabilitation trials must investigate much higher doses of the treatment than is currently attempted. 
Whilst we will hear the refrain that it is not possible to deliver such high doses in current health care settings 
(the pragmatic view), it is in fact precisely the role of clinical research to challenge what we currently do in 
order to reshape and improve our clinical services to make them better (the aspirational view). Those 
involved in stroke medicine will recognise that this is exactly the effect that thrombolysis had on acute 
management of stroke, leading to the high quality hyperacute stroke services we see today. Post-stroke 
neurorehabilitation must adopt the same aspirational approach20.
Whilst the appropriate dose of upper limb rehabilitation is debated, the content of the intervention 
receives less attention. Our approach was based on analysis of movement and performance in activities of 
daily living, reduction of impairment and re-education of quality and control of movement within activities 
of daily living, all performed in an iterative and non-linear fashion. Education, self-efficacy and goal setting 
were integral components of the programme, and we can speculate that the education and focus on self-
efficacy contributed to the continued increase in scores after treatment stopped. The therapeutic approach 
taken towards specific impairments was the same across patients, but approaches at the activity and 
participation level will necessarily vary as they are tailored to an individual’s specific meaningful goals. We 
acknowledge that an immediate challenge for us and for the field in general is to be able to define what 
the 'active ingredients' of neurorehabilitation are, so that these elements can be further tested. Our 
approach appears to have similarities with that taken by McCabe et al, with an emphasis on the quality of 
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the movement as well as the final goal of the movement. The latter is often the sole focus of task-specific 
repetition, which has been used in many upper limb rehabilitation studies to date. The evidence for 
repetitive task-specific training is of low to moderate quality21 and the effects have been disappointingly 
small even when the number of repetitions has been greatly increased8. It is difficult to tell whether this 
lack of effect is specific to task-specific training, because in general the dose (in terms of hours of active 
training) has been quite low, whether delivered by a therapist21 or robotic device22. There have been 
suggestions that chronic stroke patients might not tolerate more training than has been offered in these 
trials8, but the study of McCabe et al10 and now our own clinical experience undermine this view. 
Although this result is exciting, we must acknowledge that it is a single centre clinical service with no 
randomisation and no control group. Although there are some reports of late improvement up to 12 
months after lacunar stroke23, we expect that chronic stroke patients who are often several years after 
their stroke, will not change across this range of outcome scores without treatment. We suggest that it is 
unlikely that this magnitude of change would be seen without therapeutic intervention, but this assertion 
requires empirical confirmation. Our work however, provides strong justification for undertaking such high 
dose clinical trials. Clinic data on which to base these future studies is sorely lacking and this has led to the 
proliferation of low dose pragmatic rehabilitation studies. However, there is still much to be learned from 
published data arising from clinical services in neurorehabilitation24, making up for lack of clinical trial rigour 
with large sample sizes that are rarely achieved in clinical trials. Data from clinical services therefore have 
the potential to refine what experimental questions are addressed in future randomised clinical trials.  
Another limitation is the unblinded nature of the assessments, introducing possible bias into the results. 
All assessors are also therapists on the programme, although we ensure that assessments are carried out 
by therapists from another team who are not treating the patient. Fidelity of outcome scores is always an 
important issue in clinical trials. In our programme, we have instituted regular in-service training for FM-
UL, ARAT and CAHAI to ensure high levels of reproducibility between assessors. 
A common complaint regarding single centre clinical services is that they select only patients most likely to 
succeed. It is important to acknowledge that the QSUL programme does not have strict inclusion/exclusion 
criteria. Although our patients are generally younger than the average stroke patient and have high levels 
of independence they have a wide range of upper limb impairments. It can be seen from figures 1 and 2 
that the range of severity of the upper limb on the QSUL programme was very broad, quite unlike a clinical 
trial, although the median scores suggest that patients were weighted towards the moderate-severe end 
of upper limb impairment and activity limitation. We would argue that the QSUL programme is aspirational 
in its goals (high quality, high dose, high intensity treatment) and pragmatic in its application (wide range 
of patients admitted onto the programme). It's interesting to consider the potential impact of initial upper 
limb severity on our outcomes, but in fact, although initial score correlates well with the final score at 6 
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months (table 4), the change in score correlates only weakly with initial score (table 5, Figure 3). There are 
two ways this 'mixed-bag' approach may have potentially reduced the overall magnitude of the clinical 
effects we observed. Firstly, there may be a ceiling effect from patients with relatively high scores on 
admission. Secondly, many of our patients were quite severely impaired. Indeed, a quarter of our patients 
had an admission ARAT below 7, which suggests they have great difficulty in using their hand in any kind of 
activity of daily living. The treatment goals in these type of patients might initially be very different to the 
moderate to mild type patients, with benefits less likely to be reflected in changes in FM-UL and ARAT 
compared to the CAHAI or ArMA for example. However, the wide range of patients treated in the 
programme means that no clear patterns, in relation to differential effects on various scores, could be seen 
(Table 6, Figure 4). 
Some might argue that the wide range of responses, including those patients who changed very little, points 
to the need for stratification and selection of those patients most likely to respond, and this is certainly a 
reasonable view. However, the first point to make is that our results show that with large enough numbers 
and a high enough dose of the intervention, it is possible to demonstrate large group-level effects in 
relatively unselected populations of chronic stroke patients. Indeed, if the former (stratification) approach 
is to be adopted, then these kind of large data sets will be required to determine what the characteristics 
of the 'responders' are likely to be. The second point to make is that we found no strong clinical indicators, 
amongst our measured explanatory variables, of which patients were most likely to change, including 
sensory loss in the hand, fatigue25 and depression (tables 4 and 5). It might be that neurophysiological 
(presence or absence of motor evoked potentials)26, neuroimaging (assessment of corticospinal tract, 
whole brain damage or brain function)27–30 or cognitive (sustained attention, memory, motivation)31,32 
measures are required for accurate stratification based on likely response, and this can certainly be tested 
in future.
In summary, here we present the results from a single centre clinical service dedicated to post-stroke upper 
limb neurorehabilitation in chronic stroke patients. Despite treating patients with a wide range of 
impairment, we were able to show a large group-level magnitude of change at both the impairment and 
activity level. Our experience suggests that much higher doses and intensity of upper limb 
neurorehabilitation can be delivered and our results should inform future clinical trial design.
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FIGURE LEGENDS
Figure 1. Outcome scores for all patients. Each data point represents a single patient. Top row shows 
individual scores at admission, discharge, 6 weeks and 6 months after discharge. Bottom row shows the 
individual difference scores for admission to discharge, admission to 6 weeks post-discharge, and admission 
to 6 months post-discharge. Scores are shown for modified Fugl-Meyer (upper limb), Action Research Arm 
Test and Chedoke Arm and Hand Activity Inventory (CAHAI). Median (solid line) and upper and lower 
quartiles (dotted lines) are shown.
Figure 2. Self-reported outcome scores for all patients. Lower scores are better. Each data point represents 
a single patient. Top row shows individual scores at admission, discharge, 6 weeks and 6 months after 
discharge. Bottom row shows the individual difference scores for admission to discharge, admission to 6 
weeks post-discharge, and admission to 6 months post-discharge. Scores are shown for the Arm Activity 
Measure part A and B (ArmA-A and ArmA-B). Median (solid line) and upper and lower quartiles (dotted 
lines) are shown.
Figure 3. Admission score plotted against final scores at 6 months post-discharge for Fugl-Meyer (FM-UL), 
Action Research Arm Test (ARAT), Chedoke Arm and Hand Activity Inventory (CAHAI), Arm Activity 
Assessment A & B (ArmA-A and ArmA-B). The black line represents the line of ‘no change’. Patients above 
this line for FM-UL, ARAT and CAHAI have improved. Patients below this line for ArmA-A and ArmA-B have 
improved.
Figure 4. Change in scores from admission to 6 months post-discharge for Fugl-Meyer (FM-UL), Action 
Research Arm Test (ARAT), Chedoke Arm and Hand Activity Inventory (CAHAI), plotted against each other.  
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Difference in medians tested with Wilcoxon Signed Rank test. Difference in proportions was tested with Chi-
squared test.  Performed with ‡ 195 patients out of 224 had ArMA-A and ArMA-B measured on admission. ‡ 
‡11 patients out of 14 had ArMA-A and ArMA-B measured on admission. *202 (90.2%) patients were right 
handed, 22 (9.8%) patients were left handed.
Table 1.   Demographic and clinical  characteristics on admission
































Median time since Stroke
Months (IQR)
18 (12-51) 16 (12-22) P = 0.29
Modified Rankin Scale, n (%)
















The Barthel Index, Median (IQR), 
max = 20
19 (17-19) 19 (18-20) P = 0.12
The Neurological Fatigue Index, Median 
(IQR), max = 62
35 (25 - 42) 33 (23-38) P = 0.34
Hospital Anxiety and Depression Scale, 
Median (IQR), max = 34
12 (8-16) 13 (8.5-18) P = 0.64
Sensory Loss, n, %
             0 = Severe
             1 = Mild









(Upper Limb), Median (IQR)
max = 54
26 (16-37) 27.5 (19-34) P = 0.92
Action Research Arm Test,  Median 
(IQR), Max = 57
18 (7-33) 15 (9.5-23) P = 0.92
Chedoke  Arm and Hand Activity 
Inventory,  Median (IQR), 
Max = 91
40 (28-55) 33.5 (27-40) P = 0.37
Arm Activity Measure A,
Median (IQR), Max = 28
8 (5-12)‡ 8 (6-12)‡‡ P = 0.55
Arm Activity Measure B,
Median (IQR), Max = 52
38 (24-46)‡ 36 (29-41)‡‡ P = 0.65
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Table 2. Upper limb scores before and after admission
 Admission Discharge 6 weeks 6 months
FM-UL 26 (16 - 37) 34 (23 - 44) 35 (23 - 46) 37 (24 - 48)
ARAT 18 (7 - 33) 25 (10 - 42) 26 (11 - 44) 27 (11 - 45)
CAHAI 40 (28 - 55) 49 (36 - 70) 50 (35 - 73) 52 (35 - 77)
ArmA-A 8 (4.5 - 12) 5 (2 - 8) 4 (2 -7) 3 (1 - 6.5)
ArmA-B 38 (24 - 46) 26 (13 - 37) 21 (11 - 35) 19 (8.5 - 32)
All scores given as median (IQR)
Table 3. Changes in upper limb scores
 Adm - Dis Adm - 6 weeks Adm - 6 months
FM-UL 6 (3 to 9) 8 (4 to 11) 9 (4 to 12)
ARAT 6 (2 to 8) 7 (2 to 10) 8 (3 to 11)
CAHAI 9 (5 to 13.5) 10 (5 to 16) 12 (6 to 17)
ArmA-A -2 (-5 to -1) -3 (-6 to -1) -4 (-8 to -1)
ArmA-B -7 (-14 to -3) -10 (-17 to -4) -11 (-19 to -5)
All scores given as median (IQR)
Table 4. Correlation between baseline scores and 6 month outcomes
 FM-UL (T4) ARAT (T4) CAHAI (T4) ArmA-A (T4) ArmA-B (T4)
Age n.s. n.s. n.s. n.s. n.s.
Barthel Index n.s. n.s. 0.28 n.s. n.s.
modified Rankin Scale -0.29 -0.25 -0.32 n.s. n.s.
Neurological Fatigue Index n.s. n.s. n.s. n.s. n.s.
Hospital Anxiety and Depression Scale n.s. n.s. n.s. n.s. n.s.
Sensation n.s. n.s. 0.22 n.s. n.s.
FM-UL (T1) 0.92 0.84 0.83 -0.42 -0.63
ARAT (T1) 0.87 0.95 0.91 -0.48 -0.71
CAHAI (T1) 0.84 0.88 0.92 -0.46 -0.71
ArmA-A (T1) -0.39 -0.44 -0.44 0.56 0.41
ArmA-B (T1) -0.53 -0.58 -0.61 0.40 0.71
Correlation coefficient (rho) given only when significant at p<0.05 corrected for 55 multiple comparisons (p< 0.0009). n.s. = 
not significant
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Age n.s. n.s. n.s. n.s. n.s.
Barthel Index n.s. n.s. n.s. n.s. n.s.
modified Rankin Scale n.s. n.s. n.s. n.s. n.s.
Neurological Fatigue Index n.s. n.s. n.s. n.s. n.s.
Hospital Anxiety and Depression Scale n.s. n.s. n.s. n.s. n.s.
Sensation n.s. n.s. n.s. n.s. n.s.
FM-UL (T1) n.s. 0.40 0.45 n.s. -0.24
ARAT (T1) n.s. 0.36 0.52 n.s. n.s.
CAHAI (T1) n.s. 0.42 0.35 n.s. n.s.
ArmA-A (T1) n.s. n.s. -0.31 -0.72 n.s.
ArmA-B (T1) n.s. -0.26 -0.38 -0.28 -0.26
Correlation coefficient (rho) given only when significant at p<0.05 corrected for 55 multiple comparisons 
(p< 0.0009). n.s. = not significant












FM-UL (T1-T4) - 0.32 0.34 n.s. n.s.
ARAT (T1-T4) 0.32 - 0.37 n.s. -0.25
CAHAI (T1-T4) 0.34 0.37 - n.s. -0.20
ArmA-A(T1-T4) n.s. n.s. n.s. - 0.29
ArmA-B (T1-T4) n.s. -0.25 -0.20 0.29 -
Correlation coefficient (rho) given only when significant at p<0.05 corrected for 10 
multiple comparisons (p< 0.005). n.s. = not significant
Page 18 of 23
https://mc.manuscriptcentral.com/jnnp





























































Confidential: For Review Only
 
Outcome scores for all patients. Each data point represents a single patient. Top row shows individual scores 
at admission, discharge, 6 weeks and 6 months after discharge. Bottom row shows the individual difference 
scores for admission to discharge, admission to 6 weeks post-discharge, and admission to 6 months post-
discharge. Scores are shown for modified Fugl-Meyer (upper limb), Action Research Arm Test and Chedoke 
Arm and Hand Activity Inventory (CAHAI). Median (solid line) and upper and lower quartiles (dotted lines) 
are shown. 
600x250mm (300 x 300 DPI) 
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Self-reported outcome scores for all patients. Lower scores are better. Each data point represents a single 
patient. Top row shows individual scores at admission, discharge, 6 weeks and 6 months after discharge. 
Bottom row shows the individual difference scores for admission to discharge, admission to 6 weeks post-
discharge, and admission to 6 months post-discharge. Scores are shown for the Arm Activity Measure part A 
and B (ArmA-A and ArmA-B). Median (solid line) and upper and lower quartiles (dotted lines) are shown. 
399x250mm (300 x 300 DPI) 
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Admission score plotted against final scores at 6 months post-discharge for Fugl-Meyer (FM-UL), Action 
Research Arm Test (ARAT), Chedoke Arm and Hand Activity Inventory (CAHAI), Arm Activity Assessment A 
& B (ArmA-A and ArmA-B). The black line represents the line of ‘no change’. Patients above this line for FM-
UL, ARAT and CAHAI have improved. Patients below this line for ArmA-A and ArmA-B have improved. 
299x199mm (300 x 300 DPI) 
Page 21 of 23
https://mc.manuscriptcentral.com/jnnp





























































Confidential: For Review Only
 
Change in scores from admission to 6 months post-discharge for Fugl-Meyer (FM-UL), Action Research Arm 
Test (ARAT), Chedoke Arm and Hand Activity Inventory (CAHAI), plotted against each other.   
299x119mm (300 x 300 DPI) 
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Table	S1.	Significance	of	changes	in	outcome	scores	between	each	time	point	
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